How did TRDA's revenue and expenses shift in Q4 2024?

TRDA's revenue and expenses in Q4 2024 showed a significant shift, with a notable increase in revenue and a corresponding rise in net income, although operating expenses remained steady.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|TRDA|TRDA.O|Entrada Therapeutics|20240101-2024|Collaboration|2.10782E8|185|
|TRDA|TRDA.O|Entrada Therapeutics|20240101-2024|Collaboration|1.73384E8|185|
|TRDA|TRDA.O|Entrada Therapeutics|20240101-2024|Collaboration|1.53814E8|185|
|TRDA|TRDA.O|Entrada Therapeutics|20240101-2024|Collaboration|5.912E7|185|
|TRDA|TRDA.O|Entrada Therapeutics|20240101-2024|Collaboration|5.912E7|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|TRDA|TRDA.O|Entrada Therapeutics|2024 Q1|452.0527419838178|2.3496E7|185|
|TRDA|TRDA.O|Entrada Therapeutics|2024 Q2|312.2454489355137|5.5031E7|185|
|TRDA|TRDA.O|Entrada Therapeutics|2024 Q3|-139.5702320859536|-1.4032E7|185|
|TRDA|TRDA.O|Entrada Therapeutics|2024 Q4|111.85037720033529|1131000|185|